Cogstate Limited (ASX: CGS.AX) Stock Competitors & Peer Comparison
See CGS.AX's competitors and their performance on the ASX and across the wider stock market.
Peer Comparison Table: Medical - Healthcare Information Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for CGS.AX and its ASX peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CGS.AX | A$3.01 | +0.33% | 511.5M | 37.69 | A$0.08 | +2.00% |
| PME.AX | A$165.40 | +0.64% | 17.3B | 73.41 | A$2.25 | +0.42% |
| AYA.AX | A$3.22 | -1.53% | 524.7M | -18.82 | -A$0.17 | N/A |
| VHT.AX | A$1.15 | +0.44% | 291.3M | -28.63 | -A$0.04 | N/A |
| ONE.AX | A$0.17 | +0.00% | 149.6M | -5.97 | -A$0.03 | N/A |
| ALC.AX | A$0.10 | -4.76% | 134.4M | 59.52 | A$0.00 | N/A |
| SHG.AX | A$0.19 | -2.63% | 60M | -9.25 | -A$0.02 | N/A |
| M7T.AX | A$0.25 | -3.92% | 57.6M | -6.80 | -A$0.04 | N/A |
| DOC.AX | A$0.12 | -7.69% | 44M | 17.24 | A$0.01 | N/A |
| PKY.AX | A$0.03 | -6.25% | 37.3M | -4.76 | -A$0.01 | N/A |
Stock Comparison
Pro Medicus Limited (ASX: PME.AX)
CGS.AX vs PME.AX Comparison September 2026
Cogstate Limited (ASX: CGS.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 511.5M. In comparison, PME.AX has a market cap of 17.3B. Regarding current trading prices, CGS.AX is priced at A$3.01 on the ASX, while PME.AX trades at A$165.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 37.69, whereas PME.AX's P/E ratio is 73.41. In terms of profitability, CGS.AX's ROE is +0.22%, compared to PME.AX's ROE of +0.63%. Regarding short-term risk, CGS.AX is more volatile compared to PME.AX. This indicates higher risk in terms of short-term price fluctuations for CGS.AX.Check PME.AX's competition here
Artrya Limited (ASX: AYA.AX)
CGS.AX vs AYA.AX Comparison September 2026
Cogstate Limited (ASX: CGS.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 511.5M. In comparison, AYA.AX has a market cap of 524.7M. Regarding current trading prices, CGS.AX is priced at A$3.01 on the ASX, while AYA.AX trades at A$3.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 37.69, whereas AYA.AX's P/E ratio is -18.82. In terms of profitability, CGS.AX's ROE is +0.22%, compared to AYA.AX's ROE of -0.30%. Regarding short-term risk, CGS.AX is less volatile compared to AYA.AX. This indicates lower risk in terms of short-term price fluctuations for CGS.AX.Check AYA.AX's competition here
Volpara Health Technologies Limited (ASX: VHT.AX)
CGS.AX vs VHT.AX Comparison September 2026
Cogstate Limited (ASX: CGS.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 511.5M. In comparison, VHT.AX has a market cap of 291.3M. Regarding current trading prices, CGS.AX is priced at A$3.01 on the ASX, while VHT.AX trades at A$1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 37.69, whereas VHT.AX's P/E ratio is -28.63. In terms of profitability, CGS.AX's ROE is +0.22%, compared to VHT.AX's ROE of -0.18%. Regarding short-term risk, CGS.AX is more volatile compared to VHT.AX. This indicates higher risk in terms of short-term price fluctuations for CGS.AX.Check VHT.AX's competition here
Oneview Healthcare PLC (ASX: ONE.AX)
CGS.AX vs ONE.AX Comparison September 2026
Cogstate Limited (ASX: CGS.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 511.5M. In comparison, ONE.AX has a market cap of 149.6M. Regarding current trading prices, CGS.AX is priced at A$3.01 on the ASX, while ONE.AX trades at A$0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 37.69, whereas ONE.AX's P/E ratio is -5.97. In terms of profitability, CGS.AX's ROE is +0.22%, compared to ONE.AX's ROE of -2.04%. Regarding short-term risk, CGS.AX is less volatile compared to ONE.AX. This indicates lower risk in terms of short-term price fluctuations for CGS.AX.Check ONE.AX's competition here
Alcidion Group Limited (ASX: ALC.AX)
CGS.AX vs ALC.AX Comparison September 2026
Cogstate Limited (ASX: CGS.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 511.5M. In comparison, ALC.AX has a market cap of 134.4M. Regarding current trading prices, CGS.AX is priced at A$3.01 on the ASX, while ALC.AX trades at A$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 37.69, whereas ALC.AX's P/E ratio is 59.52. In terms of profitability, CGS.AX's ROE is +0.22%, compared to ALC.AX's ROE of +0.03%. Regarding short-term risk, CGS.AX is more volatile compared to ALC.AX. This indicates higher risk in terms of short-term price fluctuations for CGS.AX.Check ALC.AX's competition here
Singular Health Group Ltd (ASX: SHG.AX)
CGS.AX vs SHG.AX Comparison September 2026
Cogstate Limited (ASX: CGS.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 511.5M. In comparison, SHG.AX has a market cap of 60M. Regarding current trading prices, CGS.AX is priced at A$3.01 on the ASX, while SHG.AX trades at A$0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 37.69, whereas SHG.AX's P/E ratio is -9.25. In terms of profitability, CGS.AX's ROE is +0.22%, compared to SHG.AX's ROE of -0.57%. Regarding short-term risk, CGS.AX is less volatile compared to SHG.AX. This indicates lower risk in terms of short-term price fluctuations for CGS.AX.Check SHG.AX's competition here
Mach7 Technologies Limited (ASX: M7T.AX)
CGS.AX vs M7T.AX Comparison September 2026
Cogstate Limited (ASX: CGS.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 511.5M. In comparison, M7T.AX has a market cap of 57.6M. Regarding current trading prices, CGS.AX is priced at A$3.01 on the ASX, while M7T.AX trades at A$0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 37.69, whereas M7T.AX's P/E ratio is -6.80. In terms of profitability, CGS.AX's ROE is +0.22%, compared to M7T.AX's ROE of -0.24%. Regarding short-term risk, CGS.AX is less volatile compared to M7T.AX. This indicates lower risk in terms of short-term price fluctuations for CGS.AX.Check M7T.AX's competition here
Doctor Care Anywhere Group PLC (ASX: DOC.AX)
CGS.AX vs DOC.AX Comparison September 2026
Cogstate Limited (ASX: CGS.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 511.5M. In comparison, DOC.AX has a market cap of 44M. Regarding current trading prices, CGS.AX is priced at A$3.01 on the ASX, while DOC.AX trades at A$0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 37.69, whereas DOC.AX's P/E ratio is 17.24. In terms of profitability, CGS.AX's ROE is +0.22%, compared to DOC.AX's ROE of +0.91%. Regarding short-term risk, CGS.AX is more volatile compared to DOC.AX. This indicates higher risk in terms of short-term price fluctuations for CGS.AX.Check DOC.AX's competition here
Pathkey.AI Ltd (ASX: PKY.AX)
CGS.AX vs PKY.AX Comparison September 2026
Cogstate Limited (ASX: CGS.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 511.5M. In comparison, PKY.AX has a market cap of 37.3M. Regarding current trading prices, CGS.AX is priced at A$3.01 on the ASX, while PKY.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 37.69, whereas PKY.AX's P/E ratio is -4.76. In terms of profitability, CGS.AX's ROE is +0.22%, compared to PKY.AX's ROE of -0.18%. Regarding short-term risk, CGS.AX is less volatile compared to PKY.AX. This indicates lower risk in terms of short-term price fluctuations for CGS.AX.Check PKY.AX's competition here
Beamtree Holdings Limited (ASX: BMT.AX)
CGS.AX vs BMT.AX Comparison September 2026
Cogstate Limited (ASX: CGS.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 511.5M. In comparison, BMT.AX has a market cap of 30.5M. Regarding current trading prices, CGS.AX is priced at A$3.01 on the ASX, while BMT.AX trades at A$0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 37.69, whereas BMT.AX's P/E ratio is -1.67. In terms of profitability, CGS.AX's ROE is +0.22%, compared to BMT.AX's ROE of -0.58%. Regarding short-term risk, CGS.AX is more volatile compared to BMT.AX. This indicates higher risk in terms of short-term price fluctuations for CGS.AX.Check BMT.AX's competition here
Vitasora Health Limited (ASX: VHL.AX)
CGS.AX vs VHL.AX Comparison September 2026
Cogstate Limited (ASX: CGS.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 511.5M. In comparison, VHL.AX has a market cap of 30.4M. Regarding current trading prices, CGS.AX is priced at A$3.01 on the ASX, while VHL.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 37.69, whereas VHL.AX's P/E ratio is -0.97. In terms of profitability, CGS.AX's ROE is +0.22%, compared to VHL.AX's ROE of -0.49%. Regarding short-term risk, CGS.AX is less volatile compared to VHL.AX. This indicates lower risk in terms of short-term price fluctuations for CGS.AX.Check VHL.AX's competition here
Resonance Health Limited (ASX: RHT.AX)
CGS.AX vs RHT.AX Comparison September 2026
Cogstate Limited (ASX: CGS.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 511.5M. In comparison, RHT.AX has a market cap of 27.7M. Regarding current trading prices, CGS.AX is priced at A$3.01 on the ASX, while RHT.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 37.69, whereas RHT.AX's P/E ratio is 36.48. In terms of profitability, CGS.AX's ROE is +0.22%, compared to RHT.AX's ROE of +0.14%. Regarding short-term risk, CGS.AX is more volatile compared to RHT.AX. This indicates higher risk in terms of short-term price fluctuations for CGS.AX.Check RHT.AX's competition here
Emyria Limited (ASX: EMD.AX)
CGS.AX vs EMD.AX Comparison September 2026
Cogstate Limited (ASX: CGS.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 511.5M. In comparison, EMD.AX has a market cap of 26.9M. Regarding current trading prices, CGS.AX is priced at A$3.01 on the ASX, while EMD.AX trades at A$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 37.69, whereas EMD.AX's P/E ratio is -5.82. In terms of profitability, CGS.AX's ROE is +0.22%, compared to EMD.AX's ROE of -0.58%. Regarding short-term risk, CGS.AX is more volatile compared to EMD.AX. This indicates higher risk in terms of short-term price fluctuations for CGS.AX.Check EMD.AX's competition here
Corum Group Limited (ASX: COO.AX)
CGS.AX vs COO.AX Comparison September 2026
Cogstate Limited (ASX: CGS.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 511.5M. In comparison, COO.AX has a market cap of 26.3M. Regarding current trading prices, CGS.AX is priced at A$3.01 on the ASX, while COO.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 37.69, whereas COO.AX's P/E ratio is N/A. In terms of profitability, CGS.AX's ROE is +0.22%, compared to COO.AX's ROE of -0.05%. Regarding short-term risk, CGS.AX is more volatile compared to COO.AX. This indicates higher risk in terms of short-term price fluctuations for CGS.AX.Check COO.AX's competition here
PainChek Limited (ASX: PCK.AX)
CGS.AX vs PCK.AX Comparison September 2026
Cogstate Limited (ASX: CGS.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 511.5M. In comparison, PCK.AX has a market cap of 24M. Regarding current trading prices, CGS.AX is priced at A$3.01 on the ASX, while PCK.AX trades at A$0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 37.69, whereas PCK.AX's P/E ratio is -2.65. In terms of profitability, CGS.AX's ROE is +0.22%, compared to PCK.AX's ROE of -16.88%. Regarding short-term risk, CGS.AX is less volatile compared to PCK.AX. This indicates lower risk in terms of short-term price fluctuations for CGS.AX.Check PCK.AX's competition here
1st Group Limited (ASX: 1ST.AX)
CGS.AX vs 1ST.AX Comparison September 2026
Cogstate Limited (ASX: CGS.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 511.5M. In comparison, 1ST.AX has a market cap of 15.6M. Regarding current trading prices, CGS.AX is priced at A$3.01 on the ASX, while 1ST.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 37.69, whereas 1ST.AX's P/E ratio is -1.10. In terms of profitability, CGS.AX's ROE is +0.22%, compared to 1ST.AX's ROE of +0.69%. Regarding short-term risk, CGS.AX is more volatile compared to 1ST.AX. This indicates higher risk in terms of short-term price fluctuations for CGS.AX.Check 1ST.AX's competition here
MedAdvisor Limited (ASX: MDR.AX)
CGS.AX vs MDR.AX Comparison September 2026
Cogstate Limited (ASX: CGS.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 511.5M. In comparison, MDR.AX has a market cap of 14M. Regarding current trading prices, CGS.AX is priced at A$3.01 on the ASX, while MDR.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 37.69, whereas MDR.AX's P/E ratio is -0.20. In terms of profitability, CGS.AX's ROE is +0.22%, compared to MDR.AX's ROE of -2.41%. Regarding short-term risk, CGS.AX is less volatile compared to MDR.AX. This indicates lower risk in terms of short-term price fluctuations for CGS.AX.Check MDR.AX's competition here
TrivarX Limited (ASX: TRI.AX)
CGS.AX vs TRI.AX Comparison September 2026
Cogstate Limited (ASX: CGS.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 511.5M. In comparison, TRI.AX has a market cap of 13.8M. Regarding current trading prices, CGS.AX is priced at A$3.01 on the ASX, while TRI.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 37.69, whereas TRI.AX's P/E ratio is N/A. In terms of profitability, CGS.AX's ROE is +0.22%, compared to TRI.AX's ROE of -0.44%. Regarding short-term risk, CGS.AX is more volatile compared to TRI.AX. This indicates higher risk in terms of short-term price fluctuations for CGS.AX.Check TRI.AX's competition here
Intelicare Holdings Limited (ASX: ICR.AX)
CGS.AX vs ICR.AX Comparison September 2026
Cogstate Limited (ASX: CGS.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 511.5M. In comparison, ICR.AX has a market cap of 9.9M. Regarding current trading prices, CGS.AX is priced at A$3.01 on the ASX, while ICR.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 37.69, whereas ICR.AX's P/E ratio is -6.18. In terms of profitability, CGS.AX's ROE is +0.22%, compared to ICR.AX's ROE of -4.17%. Regarding short-term risk, CGS.AX is less volatile compared to ICR.AX. This indicates lower risk in terms of short-term price fluctuations for CGS.AX.Check ICR.AX's competition here
Adheris Health Limited (ASX: AHE.AX)
CGS.AX vs AHE.AX Comparison September 2026
Cogstate Limited (ASX: CGS.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 511.5M. In comparison, AHE.AX has a market cap of 8.3M. Regarding current trading prices, CGS.AX is priced at A$3.01 on the ASX, while AHE.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 37.69, whereas AHE.AX's P/E ratio is 1.16. In terms of profitability, CGS.AX's ROE is +0.22%, compared to AHE.AX's ROE of -6.14%. Regarding short-term risk, CGS.AX is more volatile compared to AHE.AX. This indicates higher risk in terms of short-term price fluctuations for CGS.AX.Check AHE.AX's competition here
Opyl Limited (ASX: OPL.AX)
CGS.AX vs OPL.AX Comparison September 2026
Cogstate Limited (ASX: CGS.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 511.5M. In comparison, OPL.AX has a market cap of 5.4M. Regarding current trading prices, CGS.AX is priced at A$3.01 on the ASX, while OPL.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 37.69, whereas OPL.AX's P/E ratio is -2.20. In terms of profitability, CGS.AX's ROE is +0.22%, compared to OPL.AX's ROE of +12.68%. Regarding short-term risk, CGS.AX is more volatile compared to OPL.AX. This indicates higher risk in terms of short-term price fluctuations for CGS.AX.Check OPL.AX's competition here
Medibio Limited (ASX: MEB.AX)
CGS.AX vs MEB.AX Comparison September 2026
Cogstate Limited (ASX: CGS.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 511.5M. In comparison, MEB.AX has a market cap of 4.5M. Regarding current trading prices, CGS.AX is priced at A$3.01 on the ASX, while MEB.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 37.69, whereas MEB.AX's P/E ratio is -0.10. In terms of profitability, CGS.AX's ROE is +0.22%, compared to MEB.AX's ROE of -0.15%. Regarding short-term risk, CGS.AX is less volatile compared to MEB.AX. This indicates lower risk in terms of short-term price fluctuations for CGS.AX.Check MEB.AX's competition here
HITIQ Limited (ASX: HIQ.AX)
CGS.AX vs HIQ.AX Comparison September 2026
Cogstate Limited (ASX: CGS.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 511.5M. In comparison, HIQ.AX has a market cap of 4.2M. Regarding current trading prices, CGS.AX is priced at A$3.01 on the ASX, while HIQ.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 37.69, whereas HIQ.AX's P/E ratio is -0.33. In terms of profitability, CGS.AX's ROE is +0.22%, compared to HIQ.AX's ROE of +1.06%. Regarding short-term risk, CGS.AX is less volatile compared to HIQ.AX. This indicates lower risk in terms of short-term price fluctuations for CGS.AX.Check HIQ.AX's competition here
TALi Digital Limited (ASX: TD1.AX)
CGS.AX vs TD1.AX Comparison September 2026
Cogstate Limited (ASX: CGS.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 511.5M. In comparison, TD1.AX has a market cap of 4.2M. Regarding current trading prices, CGS.AX is priced at A$3.01 on the ASX, while TD1.AX trades at A$0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 37.69, whereas TD1.AX's P/E ratio is -3.68. In terms of profitability, CGS.AX's ROE is +0.22%, compared to TD1.AX's ROE of -1.51%. Regarding short-term risk, CGS.AX is less volatile compared to TD1.AX. This indicates lower risk in terms of short-term price fluctuations for CGS.AX.Check TD1.AX's competition here
Careteq Limited (ASX: CTQ.AX)
CGS.AX vs CTQ.AX Comparison September 2026
Cogstate Limited (ASX: CGS.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 511.5M. In comparison, CTQ.AX has a market cap of 3.7M. Regarding current trading prices, CGS.AX is priced at A$3.01 on the ASX, while CTQ.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 37.69, whereas CTQ.AX's P/E ratio is -16.67. In terms of profitability, CGS.AX's ROE is +0.22%, compared to CTQ.AX's ROE of +0.11%. Regarding short-term risk, CGS.AX is more volatile compared to CTQ.AX. This indicates higher risk in terms of short-term price fluctuations for CGS.AX.Check CTQ.AX's competition here
Visionflex Fpo [vfx] (ASX: VFX.AX)
CGS.AX vs VFX.AX Comparison September 2026
Cogstate Limited (ASX: CGS.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 511.5M. In comparison, VFX.AX has a market cap of 3.5M. Regarding current trading prices, CGS.AX is priced at A$3.01 on the ASX, while VFX.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 37.69, whereas VFX.AX's P/E ratio is -2.00. In terms of profitability, CGS.AX's ROE is +0.22%, compared to VFX.AX's ROE of -0.84%. Regarding short-term risk, CGS.AX is more volatile compared to VFX.AX. This indicates higher risk in terms of short-term price fluctuations for CGS.AX.Check VFX.AX's competition here
Enlitic, Inc. (ASX: ENL.AX)
CGS.AX vs ENL.AX Comparison September 2026
Cogstate Limited (ASX: CGS.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 511.5M. In comparison, ENL.AX has a market cap of 3.1M. Regarding current trading prices, CGS.AX is priced at A$3.01 on the ASX, while ENL.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 37.69, whereas ENL.AX's P/E ratio is -1.23. In terms of profitability, CGS.AX's ROE is +0.22%, compared to ENL.AX's ROE of -1.39%. Regarding short-term risk, CGS.AX is less volatile compared to ENL.AX. This indicates lower risk in terms of short-term price fluctuations for CGS.AX.Check ENL.AX's competition here
Oakridge International Limited (ASX: OAK.AX)
CGS.AX vs OAK.AX Comparison September 2026
Cogstate Limited (ASX: CGS.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 511.5M. In comparison, OAK.AX has a market cap of 1.7M. Regarding current trading prices, CGS.AX is priced at A$3.01 on the ASX, while OAK.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 37.69, whereas OAK.AX's P/E ratio is N/A. In terms of profitability, CGS.AX's ROE is +0.22%, compared to OAK.AX's ROE of +0.09%. Regarding short-term risk, CGS.AX is more volatile compared to OAK.AX. This indicates higher risk in terms of short-term price fluctuations for CGS.AX.Check OAK.AX's competition here
Jayex Technology Limited (ASX: JTL.AX)
CGS.AX vs JTL.AX Comparison September 2026
Cogstate Limited (ASX: CGS.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 511.5M. In comparison, JTL.AX has a market cap of 281.3K. Regarding current trading prices, CGS.AX is priced at A$3.01 on the ASX, while JTL.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 37.69, whereas JTL.AX's P/E ratio is -0.10. In terms of profitability, CGS.AX's ROE is +0.22%, compared to JTL.AX's ROE of +0.60%. Regarding short-term risk, CGS.AX is more volatile compared to JTL.AX. This indicates higher risk in terms of short-term price fluctuations for CGS.AX.Check JTL.AX's competition here
Total Brain Limited (ASX: TTB.AX)
CGS.AX vs TTB.AX Comparison September 2026
Cogstate Limited (ASX: CGS.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGS.AX stands at 511.5M. In comparison, TTB.AX has a market cap of 267.4K. Regarding current trading prices, CGS.AX is priced at A$3.01 on the ASX, while TTB.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGS.AX currently has a P/E ratio of 37.69, whereas TTB.AX's P/E ratio is -0.02. In terms of profitability, CGS.AX's ROE is +0.22%, compared to TTB.AX's ROE of -1.05%. Regarding short-term risk, CGS.AX is more volatile compared to TTB.AX. This indicates higher risk in terms of short-term price fluctuations for CGS.AX.Check TTB.AX's competition here